Target biosecurity Identify potential partnerships with pharmaceutical and biotech firms seeking advanced enzyme delivery and genetic disease solutions, leveraging Iditarod Bio's focus on deep learning engineered enzymes delivered to the lung to complement existing programs.

Leverage AI biology Position Iditarod Bio as a partner for AI-driven protein engineering and enzyme design, offering access to specialized computational biology capabilities to accelerate therapeutic development for respiratory and metabolic diseases.

Early-stage collaboration Highlight opportunities for collaboration with venture-backed startups and growth-stage biotech companies needing cost-efficient R&D capabilities, given the company’s small size and recent funding momentum.

Cost-efficient scale Offer modular, scalable engagement models (research projects, sponsored R&D, or milestone-based collaborations) that align with the company’s modest revenue range and current funding of around $17M.

Strategic alignments Target competitors and adjacent players in CRISPR and gene therapy spaces seeking novel enzyme delivery mechanisms; propose joint development or licensing discussions to diversify portfolios and accelerate clinical timelines.